The Patient Perspective: Putting the Patient at the Center of the Translational Innovation Process

Clin Pharmacol Ther. 2020 Jan;107(1):82-84. doi: 10.1002/cpt.1686. Epub 2019 Nov 23.


After centuries of physicians believing that they know what is best for patients, this paternalistic approach to patient care is being challenged. The explosion in readily accessible information has resulted in patients being empowered to take on a greater role in decision making, from clinical care to regulatory decision making. The Centers of Excellence in Regulatory Science and Innovation (CERSIs) are collaborating with the US Food and Drug Administration (FDA) to promote patient engagement and advance patient preference research.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Diffusion of Innovation
  • Drug Approval
  • Humans
  • Natalizumab / adverse effects
  • Natalizumab / therapeutic use
  • Organizational Innovation
  • Patient Participation*
  • Patient Preference
  • Translational Research, Biomedical*
  • United States
  • United States Food and Drug Administration
  • Universities


  • Natalizumab